doi:10.15326/jcopdf.2021.0259exacerbationsCOPD Assessment Testpatient-reported outcomessingle-inhaler triple therapyIMPACT trialBackground: In the InforMing the PAthway of COPD Treatment (IMPACT) trial, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) reduced moderate/severe exacerbation...
1). Following a feasibility assessment, a total of 23 trials identified from the SLR and internet searches were included in the NMA. Fig. 1 PRISMA flowchart. CSR clinical study report, GSK GlaxoSmithKline, LABA long-acting β2-agonist, LAMA long-acting muscarinic antagonist, NMA network meta-...
Full size table Im zweiten Schritt erfolgt die Zuteilung zu einer der Risikogruppen A, B, C oder D. Hierfür erfolgt eine standardisierte Symptomquantifizierung mittels des COPD Assessment Tests (CAT), welcher über 8 Fragen die individuelle Symptomatik des COPD-Patienten mit 0–40 Punkten...
(COPD Assessment Test [CAT] scale, 0 to 40 with ≤5 being the norm for healthy nonsmokers and >30 indicating a very high COPD effect on quality of life, MCID is 2 units)21; modified Medical Research Council (mMRC) dyspnea score (range, 0 [not troubled by breathlessness except on ...
The objective of this study was to assess the validity and performance of the Arabic and Turkish versions of the COPD Assessment Test (CAT) for evaluating the severity and impact of COPD symptoms. The data were obtained from the BREATHE study in the Middle East and North Africa region, a la...
Abbreviation: CAT, COPD Assessment Test. Eosinophil count <150 cells/µL Eosinophil count ≥150 cells/µL Eosinophil count ≥300 cells/µL 0 exacerbations 1 exacerbation ≥2 exacerbations n=46 n=15 n=23 34.8% n=106 60.0% n=63 82.6% n=99 35.8% 60.3% 72.7% n=38 23.7% n=32 ...
SAQ-COPD questionnaire shows a test-retest reliability of 0.68, a moderate ICC given that in general for reliability to be considered good it should have exceeded 0.75.31 However, in the specific case of the assessment of PA instruments, 0.70 has been suggested as a su...
39 Though three-quarters of our cohort were prescribed augmentation therapy, this is unlikely to have impacted on the prevalence of cardiovascular disease as most patients started augmentation therapy within 1 year of baseline assessment. There may also be underdiagnosis of cardiov...
Following the principles of multidimensional assessment, GesEPOC proposes a severity classification with 5 different levels, whose main determinant for severity is the BODE index and its different quartiles.30 With the lack of information about the distance walked in the 6-min walk test, GesEPOC re...
Noteworthy, some information on comorbidities and COPD phenotypes can be derived from simple information such as the categorization into GOLD groups, or the modified Medical Research Council (mMRC) scale, or single questions of the COPD Assessment Test (CAT) [8,9,10]. The fact that symptoms of...